Levetiracetam is available as regular and extended release oral formulations and as intravenous formulations.
The immediate release tablet has been available as a generic in the United States since 2008, and in the UK since 2011. The patent for the extended release tablet will expire in 2028.
The branded version Keppra is manufactured by UCB Pharmaceuticals S.A.
In 2015, Aprecia's 3D-printed orally disintegrating tablet form of the drug was approved by the FDA, under the trade name Spritam. Some have said that the drug has been improved by 3D printing, as the formula used now has improved disintegration properties.